CD274 and head and neck squamous cell carcinoma: Anti-programmed death ligand-1 (anti-PD-L1) checkpoint inhibitors such as durvalumab and avelumab have been approved for the treatment of patients with locally advanced or metastatic HNSCC under phase III clinical trials since 2017 (8).